Literature DB >> 1163425

The effect of congestive heart failure on quinidine pharmacokinetics.

W G Crouthamel.   

Abstract

Quinidine is an effective antiarrhythmic agent whose therapeutic effects and toxicity have been related to its serum concentrations. Many patients with cardiac arrhythmias also suffer from congestive heart failure. It is well documented that congestive heart failure can reduce blood perfusion to many regions of the body, and could conceivably alter drug pharmacokinetics. A pharmacokinetic evaluation of two sets of quinidine data in congestive heart failure patients indicates that congestive heart failure reduced the rate of absorption and volume of distribution following oral or intramuscular administration of quinidine. Furthermore, the amount of quinidine absorbed following oral administration is reduced, but congestive heart failure does not appear to alter the elimination rate of quinidine. The interpretation of the data presented herein strongly suggests that the site of administration, extent of distribution, and rate of absorption must be considered when determining dosage regimens in congestive heart failure patients since normal dosages in these patients result in abnormally high serum quinidine concentrations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1163425     DOI: 10.1016/0002-8703(75)90322-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

3.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

6.  Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure.-.

Authors:  O Brørs; S Jacobsen; E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

7.  Absolute bioavailability of quinidine in two sustained release preparations.

Authors:  J P Amlie; L Storstein; B Olsson; D Fremstad; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

9.  Bioavailability of quinidine in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.